Therefore, the effects of any potential immunostimulation from radiotherapy in HNSCC may concurrently be reduced by STAT‐3 signalling pathway, PD‐L1 upregulation and CCL2/MCP1 expression on MDSC. The gene discussed is CCL2; the disease is head and neck squamous cell carcinoma.